T8663

Nifenalol.HCl(INPEA) is a antagonist of β-adrenergic receptor.

HSD17B13-IN-40 (compound 6) serves as a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of less than 0.1 μM using estradiol as substrates. This compound is significant in the treatment of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH) [1].

HSD17B13-IN-41 (Compound C) serves as an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). This compound is utilized in studies related to liver, metabolic, and cardiovascular diseases, including NAFLD and NASH [1].

HSD17B13-IN-42 (compound 10) is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), with an IC50 of < 0.1 μM using estradiol as substrates. HSD17B13-IN-42 plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) [1].

HSD17B13-IN-43 (11) serves as an inhibitor of 17β-Hydroxysteroid dehydrogenases (HSD17B13), demonstrating potent activity with an IC 50 of <0.1 μM against Estradiol. It is primarily utilized in the study of NAFLD (Nonalcoholic fatty liver diseases) [1].

HSD17B13-IN-44 (Compound 23) functions as an inhibitor targeting hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of < 0.1 μM against estradiol. This compound is applicable in the study of liver diseases or metabolic disorders [1].

HSD17B13-IN-46 (Compound 351), an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibits potent activity with an IC50 value of < 0.1 μM for estradiol. This compound is utilized for studying liver diseases or metabolic disorders [1].

HSD17B13-IN-47 (Compound 500), an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrates potent activity with an IC 50 value of < 0.1 μM against estradiol. It is applicable in the study of liver diseases or metabolic disorders [1].

HSD17B13-IN-48 (Compound 12) serves as an inhibitor for hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC50 value of ≤ 0.1 μM against estradiol. This compound is applicable in the study of liver, metabolic, and cardiovascular diseases, including NAFLD, NASH, and drug-induced liver injury (DILI) [1].

HSD17B13-IN-49 (Compound 81) acts as an inhibitor targeting hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC50 value of ≤ 0.1 μM for estradiol. It is utilized in studies exploring liver, metabolic, and cardiovascular diseases, including NAFLD, NASH, and drug-induced liver injury (DILI) [1].